A Gene Therapy Death

By Silberner, Joanne | The Hastings Center Report, March 2000 | Go to article overview
Save to active project

A Gene Therapy Death


Silberner, Joanne, The Hastings Center Report


It was what the New York Times headlined a biotech death. Eighteen-year-old Jesse Gelsinger died four days after receiving gene therapy for a rare metabolic disorder. It was also the first death associated with gene therapy. As details of the experiment and the death unfolded, with often contradictory information, the field of gene experimentation appeared neither orderly nor well regulated.

Gelsinger had a rare metabolic disorder called ornithine transcarbamylase deficiency, which prevents the normal breakdown of ammonia. Children born with the condition often die a quick death, but Gelsinger had a mild form, controlled by drugs and a rigorous low-protein diet. Nonetheless, the diet and drugs were tough on a teenager striving to lead a normal life. As it happened, the University of Pennsylvania was working on a protocol in which volunteers with forms of the OTC deficiency similar to Gelsinger's would receive a healthy copy of the OTC gene, delivered via adenovirus. Gelsinger signed up for the gene therapy study, and it shut down his organs one by one, and killed him.

Twelve days after Gelsinger's death, the Washington Post got wind of the story and began uncovering a series of ethically questionable features of the protocol. The Recombinant DNA Advisory Committee had discussed the experiment at a meeting in 1995 and eventually approved it. But the Post discovered that a member of the committee had expressed concern about trying such a novel treatment on people who were not critically ill. The decision to work with adults who were relatively well rather than with infants who had the quickly fatal form of the disease turned out to be the result of the university's own ethics committee. The committee had ruled that parents could not possibly make a rational decision about the risks of the experiment.

Also, the RAC had recommended that the genetic material be delivered via an intravenous line rather than a catheter into the liver, as the researchers had planned. Only after Gelsinger's death did RAG members learn that the Penn researchers, in consultation with the Food and Drug Administration, had used the catheter route after all, in an effort to avoid side effects.

There were other perhaps even more egregious problems. Monkeys that had received a similar adenovirus had died of blood and liver complications, and while the consent form shown to reviewers had mentioned this fact, it did not appear on the form signed by Gelsinger. Further, FDA officials said that on the day before the injection, Gelsinger's ammonia levels had risen above the maximum allowed by the protocol.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

A Gene Therapy Death
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?